Twist Bioscience Co. (NASDAQ:TWST) Shares Bought by Stifel Financial Corp

Stifel Financial Corp lifted its stake in shares of Twist Bioscience Co. (NASDAQ:TWST) by 11.8% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 6,967 shares of the company’s stock after buying an additional 734 shares during the quarter. Stifel Financial Corp’s holdings in Twist Bioscience were worth $315,000 as of its most recent filing with the SEC.

Several other hedge funds have also modified their holdings of the stock. Thrivent Financial for Lutherans purchased a new stake in Twist Bioscience during the 3rd quarter worth $43,992,000. Point72 Asset Management L.P. grew its stake in Twist Bioscience by 1,021.8% during the 2nd quarter. Point72 Asset Management L.P. now owns 673,057 shares of the company’s stock valued at $33,168,000 after purchasing an additional 613,057 shares in the last quarter. Fred Alger Management LLC raised its position in shares of Twist Bioscience by 720.7% in the 2nd quarter. Fred Alger Management LLC now owns 654,877 shares of the company’s stock valued at $32,272,000 after purchasing an additional 575,080 shares in the last quarter. Victory Capital Management Inc. grew its position in shares of Twist Bioscience by 4,133.1% during the second quarter. Victory Capital Management Inc. now owns 308,171 shares of the company’s stock worth $15,187,000 after buying an additional 300,891 shares in the last quarter. Finally, Farallon Capital Management LLC acquired a new stake in Twist Bioscience in the second quarter valued at $9,462,000.

Twist Bioscience Stock Performance

Shares of NASDAQ:TWST opened at $48.17 on Friday. Twist Bioscience Co. has a 52 week low of $27.41 and a 52 week high of $60.90. The company has a market cap of $2.86 billion, a PE ratio of -13.38 and a beta of 1.82. The firm has a 50 day simple moving average of $45.61 and a 200 day simple moving average of $46.72.

Wall Street Analyst Weigh In

Several research analysts have recently commented on the company. Leerink Partners lifted their target price on Twist Bioscience from $45.00 to $48.00 and gave the stock a “market perform” rating in a research report on Thursday, October 17th. TD Cowen restated a “buy” rating and issued a $58.00 price target on shares of Twist Bioscience in a research report on Tuesday, November 26th. Barclays lowered their price objective on shares of Twist Bioscience from $55.00 to $52.00 and set an “overweight” rating for the company in a research report on Tuesday, November 19th. Scotiabank lifted their target price on Twist Bioscience from $50.00 to $54.00 and gave the company a “sector outperform” rating in a research note on Tuesday, November 19th. Finally, Robert W. Baird increased their price target on Twist Bioscience from $46.00 to $48.00 and gave the stock an “outperform” rating in a research report on Tuesday, November 19th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $51.90.

Insiders Place Their Bets

In other news, insider Dennis Cho sold 659 shares of the business’s stock in a transaction on Monday, November 4th. The shares were sold at an average price of $41.56, for a total transaction of $27,388.04. Following the transaction, the insider now directly owns 94,481 shares in the company, valued at $3,926,630.36. The trade was a 0.69 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, SVP Paula Green sold 860 shares of the business’s stock in a transaction that occurred on Friday, December 6th. The shares were sold at an average price of $52.70, for a total value of $45,322.00. Following the completion of the sale, the senior vice president now directly owns 133,715 shares of the company’s stock, valued at approximately $7,046,780.50. The trade was a 0.64 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 101,911 shares of company stock worth $4,585,717. 3.92% of the stock is currently owned by company insiders.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.